MedTrace Logo

Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer

NCT03042169 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-12-23

No results posted yet for this study

Summary

Surgical resection of the primary tumour and treatment of the metastatic site in oligometastatic stage IV metastatic gastric adenocarcinoma enhances survival and improves quality of life with acceptable postoperative morbidity and mortality in a selected group of operable patients with only one metastatic site that does not progress under chemotherapy.

Conditions

  • Gastric Adenocarcinoma

Interventions

DRUG

Preoperative Chemotherapy

Standard chemotherapy regiments according to risk of recurrence

PROCEDURE

Surgery

the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.

DRUG

Postoperative chemotherapy

Chemotherapy should be restarted between D1 and D30 post-randomization

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Guillaume Piessen, MD,PhD · University Hospital, Lille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-25
Primary Completion
2024-08-28
Completion
2024-08-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03042169 on ClinicalTrials.gov